

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**


Defective images within this document are accurate representations of the original documents submitted by the applicant.


Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**





IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Edward Houston                      Group No.: 1723  
Application No.: 10/662,553  
Filed: September 15, 2003                      Examiner: Not Yet Assigned  
For: PSORIASIS TREATMENT AND METHOD OF PREPARATION

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

TRANSMITTAL OF CERTIFIED COPIES

Attached please find the certified copy of the foreign application from which priority is claimed for this case:

Country: United Kingdom  
Application Number: GB 0217372.2  
Filing Date: July 25, 2002

WARNING: "When a document that is required by statute to be certified must be filed, a copy, including a photocopy or facsimile transmission of the certification is not acceptable." 37 C.F.R. section 1.4(f) (emphasis added).

---

CERTIFICATE OF MAILING (37 C.F.R. SECTION 1.8a)

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Date: Feb. 17, 2004

George Chacles  
(type or print name of person mailing paper)

George Chacles  
Signature of person mailing paper



  
SIGNATURE OF PRACTITIONER

Reg. No.: 46,608

George N. Chaclas

*(type or print name of practitioner)*

Tel. No.: (860) 541-7720

EDWARDS & ANGELL, LLP

P.O. Box 55874

P.O. Address

Customer No.: 21874

Boston, MA 02205

*NOTE: "The claim to priority need be in no special form and may be made by the attorney or agent, if the foreign application is referred to in the oath or declaration, as required by section 1.63." 37 C.F.R. section 1.55(a).*





INVESTOR IN PEOPLE

The Patent Office  
Concept House  
Cardiff Road  
Newport  
South Wales  
NP10 8QQ

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.


Signed 

Dated 22 January 2004





Patents Form 1/77

Patents Act 1977  
(Rule 18)

CANCELLED

29JUL02 E736476-1 D10002  
P01/7700 0.00-0217372.2**Request for grant of a patent**

See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form.

EFFECTIVE  
PFI/PZ

25 JUL 2002

The Patent Office

Cardiff Road  
Newport  
South Wales  
NP10 8QQ

1. Your reference **dor.2251.uk.cr.d**
2. Patent application number  
(The Patent Office will fill in this part) **0217372.2**
3. Full name, address and postcode of the or of each applicant (include the full surname)  
**Edward Houston**  
**114 Main Street**  
**Condorrat**  
**Cumbernauld**  
**GLASGOW**  
**G67 4SY**  
**UK**  
**8198525001**
- Patents ADP number (if you know it)
- If the applicant is a corporate body, give the country/state of its incorporation
4. Title of the invention **Psoriasis formulation and method of preparation**
5. Name of your agent (if you have one) **Kennedys Patent Agency Limited**  
**Floor 5, Queens House**  
**29 St Vincent Place**  
**GLASGOW**  
**G1 2DT**  
**8058240001**
- "Address for service" in the United Kingdom to which all correspondence should be sent (including the postcode)
- Patents ADP number (if you know it)
6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and (if you know it) the or each application number
- | Country | Priority application number (if you know it) | Date of filing (day / month / year) |
|---------|--|-------------------------------------|
|         |  |                                     |
7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application
- | Number of earlier application | Date of filing (day / month / year) |
|-------------------------------|-------------------------------------|
|                               |                                     |
8. Is a statement of inventorship and of right to grant of a patent required in support of this request? (Answer "Yes" if:  
a) any applicant named in part 3 is not an inventor, or  
b) there is an inventor who is not named as an applicant, or  
c) any named applicant is a corporate body.  
See note (d)) **Yes**

Patents Form 1/77

**Patents Form 1/77**

9. Enter the number of sheets for any of the following items you are filing with this form. Do not count copies of the same document

Continuation sheets of this form

Description 7

Claim(s)

Abstract

Drawing(s) 1

10. If you are also filing any of the following, state how many against each item.

Priority documents

Translations of priority documents

Statement of inventorship and right to grant of a patent (Patents Form 7/77)

Request for preliminary examination and search (Patents Form 8/77)

Request for substantive examination (Patents Form 10/77)

Any other documents (please specify)

11.

I/We request the grant of a patent on the basis of this application

Signature

KENNEDYS

Date

25 July 2002

12. Name and daytime telephone number of person to contact in the United Kingdom

Claire Rutherford

0141 226 6826

**Warning**

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

**Notes**

- If you need help to fill in this form or you have any questions, please contact the Patent Office on 08459 500505.
- Write your answers in capital letters using black ink or you may type them.
- If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- If you have answered 'Yes' Patents Form 7/77 will need to be filed.
- Once you have filled in the form you must remember to sign and date it.
- For details of the fee and ways to pay please contact the Patent Office.

**Patents Form 1/77**

1 Psoriasis Formulation and Method of Preparation

2

3 This invention relates to formulations which can be used  
4 in the treatment of dermatological disorders, such as  
5 psoriasis. The current invention also relates to a  
6 method of preparation that is more acceptable for use  
7 than many current treatments.

8

9 The term dermatological disorders covers a wide range of  
10 disorders, such as psoriasis and eczema. These disorders  
11 affect a large number of people. Psoriasis is a chronic  
12 recurring skin disease, the scope of which can vary  
13 considerably from mild outbreaks, to severe cases.

14

15 The underlying problem of psoriasis is currently thought  
16 to be that new skin cells are produced too quickly, so  
17 that the old skin cells have not had time to die off and  
18 be removed. The resulting overproduction of skin cells  
19 is red and raised patches on the skin.

20

21 Various treatments have been suggested for psoriasis. In  
22 particular, many sufferers find that coal tar has a  
23 particularly beneficial effect and improves many of the

1 symptoms of psoriasis. Unfortunately, although coal tar  
2 has been found to be effective against the symptoms of  
3 psoriasis in many patients, as a substance coal tar is  
4 not the most user friendly. Coal tar has a very pungent  
5 smell and has a black colour which stains both clothing  
6 and bed linen. This can be very off-putting for many  
7 psoriasis sufferers and is generally inconvenient for  
8 regular use.

9

10 It can therefore be seen that it would be beneficial to  
11 provide a psoriasis treatment which contains coal tar,  
12 but which is formulated in a manner which is appropriate  
13 for regular use.

14

15 It is an object of the present invention to provide a  
16 psoriasis treatment which comprises coal tar.

17

18 A further object of the present invention is to provide a  
19 psoriasis treatment in a formulation which does not stain  
20 clothes and is not unpleasant smelling.

21

22 A yet further object of the present invention is to  
23 provide a psoriasis treatment in a formulation that can  
24 be easily applied.

25

26 According to a first aspect of the present invention,  
27 there is provided a method of preparing a psoriasis  
28 formulation comprising coal tar and zinc pyrithione,  
29 wherein the coal tar is filtered to remove impurities by  
30 filter compression.

31

32 Preferably the coal tar is filtered by being fed through  
33 a compressed charcoal filter.

1  
2 Most preferably the coal tar is fed through the filter at  
3 17 to 19 psi.

4  
5 Most preferably the coal tar is fed through the filter at  
6 18 psi..

7  
8 Preferably compressed air is used to force the coal tar  
9 through the filter.

10  
11 Preferably the coal tar is left in the filter system for  
12 8 hours.

13  
14 Preferably the filtered fluid is boiled.

15  
16 Most preferably the filtered fluid is boiled for 5  
17 minutes.

18  
19 Preferably the boiled, filtered fluid is allowed to cool  
20 to room temperature.

21  
22 Most preferably the top layer of the boiled, filtered  
23 fluid is refiltered.

24  
25 Optionally, refiltering is through a nylon mesh.

26  
27 Preferably a surfactant is added to the formulation.

28  
29 Preferably the surfactant is an ionic surfactant.

30  
31 Most preferably the surfactant is sodium lauryl sulphate.

32  
33 Preferably a carrier is added to the formulation.

1

2 Most preferably multiple carriers are added to the  
3 formulation.

4

5 Optionally a carrier may be isopropyl myristate.

6

7 A further option is that a carrier may be ethyl alcohol.

8

9 Preferably the psoriasis formulation is placed in a spray  
10 or aerosol container.

11

12 According to a second aspect of the present invention,  
13 there is provided a composition for the treatment of  
14 dermatological disorders, comprising:

15

- 16 (a) coal tar;
- 17 (b) zinc pyrithione;
- 18 (c) one or more surfactants; and
- 19 (d) one or more carriers

20

21 Preferably the psoriasis formulation also contains  
22 allantoin.

23

24 Preferably the surfactant is an ionic surfactant.

25

26 Most preferably the surfactant is sodium lauryl sulphate.

27

28 Optionally a carrier may be isopropyl myristate.

29

30 A further option is that a carrier may be ethyl alcohol.

31

32 Preferably the psoriasis formulation will also comprise  
33 an anti-fungal agent.

1  
2 Preferably the anti-fungal agent is undecylenic acid.  
3  
4 Preferably the psoriasis treatment formulation comprises  
5 the following ingredients:

6  
7 zinc pyrithione;  
8 alcoholic extract of coal tar;  
9 allantoin;  
10 sodium lauryl sulphate;  
11 isopropyl myristate;  
12 ethyl alcohol; and  
13 undecylenic acid

14  
15 Preferably the psoriasis formulation comprises the  
16 following ingredients in the following amounts:

|    |                               |        |
|----|-------------------------------|--------|
| 17 |                               |        |
| 18 | zinc pyrithione               | 0.20%  |
| 19 | alcoholic extract of coal tar | 0.25%  |
| 20 | allantoin                     | 0.25%  |
| 21 | sodium lauryl sulphate        | 0.10%  |
| 22 | isopropyl myristate           | 49.45% |
| 23 | ethyl alcohol                 | 49.45% |
| 24 | undecylenic acid              | 0.30%  |
| 25 |                               |        |

26 Preferably the psoriasis formulation is provided in a  
27 spray form.

28

29 Alternatively, the psoriasis formulation is provided in  
30 an aerosol form.

31

1 In order to provide a better understanding of the present  
2 invention, embodiments will now be described by way of  
3 example only, and with reference to the following Figure:

4  
5 Figure 1 shows a charcoal filter system for use according  
6 to the first aspect of the present invention.

7  
8 Coal tar, when untreated, has a very pungent smell and is  
9 black in colour. The black colouring will stain clothing  
10 and bed linen on contact.

11  
12 In order to produce an acceptable formulation for use in  
13 treating psoriasis or other dermatological disorders,  
14 coal tar is filtered in order to eradicate the smell and  
15 remove many of the impurities which result in staining.

16  
17 In the preferred embodiment, crude coal tar is mixed with  
18 2%sd alcohol (which acts as a thinner and is poured into  
19 a charcoal filter system 1 via the coal tar input 2.  
20 Clean, compressed air is then applied via the air input 3  
21 at 18 psi (which can be varied between 17 to 19 psi).

22  
23 The charcoal filter system 1 comprises a fine mesh gauze  
24 filter 4 and a charcoal filter 5 which the coal tar  
25 mixture is pushed through into the catch tank 6. It is  
26 worth noting that too much pressure forces charcoal  
27 through the system and too little does not push the coal  
28 tar mixture through.

29  
30 The system 1 is left in place overnight with the  
31 compressed air still in place. In the preferred  
32 embodiment, the system is left for approximately 8 hours.  
33 The filtered fluid is then taken from the catch tank 6



1 via the exit flow tap 7 and is boiled (in the preferred  
2 embodiment it is boiled for 5 minutes) and left to  
3 completely cool to room temperature. The fluid now has a  
4 scum on top which is filtered through a nylon mesh to  
5 give a clear, completely odourless liquid which does not  
6 stain materials.

7

8 A surfactant and a carrier is then added to make the  
9 formulation completely soluble. In the preferred  
10 embodiment, the surfactant is an ionic surfactant, sodium  
11 lauryl sulphate. Multiple carriers are used, and in the  
12 preferred embodiment, these are isopropyl myristate and  
13 ethyl alcohol. Zinc pyrithione is also added to the  
14 formulation, which increases the effectiveness of the  
15 formulation to a previously unexpected degree. Allantoin  
16 is also added to the formulation.

17

18 In the preferred embodiment, an anti-fungal agent is also  
19 added to the formulation. This anti-fungal agent is  
20 undecylenic acid in the preferred embodiment.




71  
**INFORMAL**

Figure 1

